For many investors, the experimental psychedelics industry may be too risky to invest in. Most companies in this sector are privately held, and psychedelic stocks are often volatile penny or OTC stocks.
Aside from being risky, these stocks can also be difficult to purchase. Most stocks will require you to have a brokerage account that offers access to OTC and international stocks, like Interactive Brokers or TradeStation.
For investors willing to take the risk, the best psychedelic stocks depend on your portfolio and investment goals — while volatility can be ideal for day traders, long-term investors will want to look to stocks with steadier gains over time.
Top 7 stocks of Dec 2024
The top
experimental drug
stocks included on this page all trade on the S&P 500, have an analyst recommendation of "Buy" or better and are sorted by year-to-date performance.
Terms apply. Cryptoassets are highly volatile. Your capital is at risk. Available in the US, CA, UK and AU
Disclaimer: This page is not financial advice or an endorsement of digital assets, providers or services. Digital assets are volatile and risky, and past performance is no guarantee of future results. Potential regulations or policies can affect their availability and services provided. Talk with a financial professional before making a decision. Finder or the author may own cryptocurrency discussed on this page.
Sign up for an account. Provide your personal information and sign up.
Set up a funding method to pay for the transaction. Deposit funds into your account by linking your banking information.
Choose the stocks you want to buy. Search for the stock by name or ticker symbol like CMPS or MMEDF.
Place your order. Buy the stock. It's that simple.
Take a deeper dive into psychedelic stocks
If you're interested in investing in the experimental drug industry, take a closer look at what companies in this industry do and how the stocks have historically performed. Keep in mind that positive past performance doesn't guarantee that a stock will continue to rise in the future.
1. Compass Pathways Plc (CMPS)
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020.
Compass Pathways Plc stock opened the day at $3.91 after a previous close of $3.93. The latest price was $3.97 (25-minute delay). Compass Pathways Plc is listed on the NASDAQ and employs 186 staff.
Mind Medicine (MindMed) Inc. , a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC.
Mind Medicine MindMed stock opened the day at $0.00 after a previous close of $0.00. The latest price was $0.00 (25-minute delay). Mind Medicine MindMed is listed on the OTCQB and employs 22 staff.
Mycotopia Therapies Inc. provides psychedelic therapies through technology-focused, data-driven, and medical-based solutions for people dealing with anxiety, depression, bipolar disorders, PTSD, ADHD, autism, and addictions. The company was incorporated in 2019 and is based in Aventura, Florida.
Mycotopia Therapies stock opened the day at $0.00 after a previous close of $0.00. The latest price was $0.00 (25-minute delay). Mycotopia Therapies is listed on the PINK and employs 1 staff.
Numinus Wellness Inc. provides solutions to develop and deliver psychedelic-assisted psychotherapy and transform the mental health landscape. The company operates in two divisions, Salvation Botanicals and Numinus Health.
Numinus Wellness stock opened the day at C$0.00 after a previous close of C$0.00. The latest price was C$0.00 (25-minute delay). Numinus Wellness is listed on the V and has a trailing 12-month revenue of around CAD$1.5 million. All prices are listed in Canadian Dollars.
Mindset Pharma Inc. develops and sells psychedelic medicines to treat neurological and psychiatric disorders in Canada. It focuses on developing MSP-1014, a psychedelic drug candidate.
Mindset Pharma stock opened the day at C$0.00 after a previous close of C$0.00. The latest price was C$0.00 (25-minute delay). Mindset Pharma is listed on the CN and has a trailing 12-month revenue of around CADC$7.8 million. All prices are listed in Canadian Dollars.
Cybin Inc. , a biotechnology company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Cybin U. S.
Cybin stock opened the day at $0.00 after a previous close of $0.00. The latest price was $0.00 (25-minute delay). Cybin is listed on the OTCQB, has a trailing 12-month revenue of around USDC$864,000 and employs 38 staff.
Field Trip Health Ltd. engages in the development and delivery of psychedelic therapies. Its Research division is involved in the development of psychedelic molecules and conducting research on plant-based psychedelics.
Field Trip Health stock opened the day at C$0.00 after a previous close of C$0.00. The latest price was C$0.00 (25-minute delay). Field Trip Health is listed on the CN and has a trailing 12-month revenue of around CAD$435,460. All prices are listed in Canadian Dollars.
While it’s possible to turn a profit investing in psychedelic stocks, keep in mind that — like any investment — psychedelic stocks are not immune to risk. These stocks are subject to fluctuating conditions — both in the market and in the experimental drug industry, so carefully vet your picks before you invest. And if you’re new to investing, or if it’s been awhile since you’ve taken a critical look at your investing accounts, compare brokers to make sure you’re getting the best features in your trading account.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
How likely would you be to recommend Finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
Advertiser disclosure
Finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which Finder receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. Finder compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
